Related Experiment Video

Updated: Jul 19, 2026

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

Kinase inhibitors for cardiovascular disease

Rajesh Kumar1, Vivek P Singh, Kenneth M Baker

  • 1Division of Molecular Cardiology, Cardiovascular Research Institute, Texas A&M University System Health Science Center, College of Medicine, Temple, TX 76504, USA.

Journal of Molecular and Cellular Cardiology
|October 25, 2006
PubMed

Insights

Understanding cellular responses and signal transduction in cardiovascular diseases (CVDs) reveals new therapeutic targets. Protein kinase inhibitors offer a promising approach for CVD treatment by selectively targeting signaling pathways.

Area of Science:

  • Cardiovascular Biology
  • Molecular Medicine
  • Cell Signaling

Background:

  • Cardiovascular diseases (CVDs) understanding has advanced, with neurohormonal stimulation implicated in pathophysiology.
  • Current effective treatments include blocking the renin-angiotensin and beta-adrenergic systems.
  • Cellular responses to the extracellular environment and signal transduction are key to novel therapeutic strategies.

Purpose of the Study:

  • To review potential protein kinase targets for cardiovascular disease (CVD) treatment.
  • To explore the therapeutic potential of selectively targeting cell signaling pathways.
  • To highlight recent evidence supporting interventional value in CVDs.

Main Methods:

  • Review of current literature on cell signaling in cardiovascular diseases.
  • Analysis of protein kinase pathways involved in CVD pathophysiology.
  • Evaluation of evidence for therapeutic interventions targeting protein kinases.

Main Results:

  • Multiple cell signaling cascades exist, with both beneficial and deleterious effects in CVDs.
  • The balance of these pathways, influenced by the cellular environment, dictates disease outcomes.
  • Selective targeting of signaling pathways via protein kinase inhibitors shows potential advantages over receptor blockers.

Conclusions:

  • Protein kinase inhibitors represent a promising therapeutic avenue for cardiovascular diseases.
  • Understanding and modulating cell signaling pathways are crucial for developing novel CVD treatments.
  • Further research into specific protein kinase targets could lead to more effective interventions for CVDs.

More Related Videos

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

Enhancing the Engraftment of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes via a Transient Inhibition of Rho Kinase Activity08:00

Enhancing the Engraftment of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes via a Transient Inhibition of Rho Kinase Activity

Published on: July 10, 2019

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However, frequent irregular...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...